Business Wire1mon
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial ...
GSM Arena2y
Xiaomi Mi Mix 2
Build Glass front (Gorilla Glass 4), ceramic back, aluminum frame Glass front (Gorilla Glass 4), ceramic back, ceramic frame - 128/8 GB model ...